Unichem Pharmaceuticals (USA) Initiates Nationwide Class III Recall for Doxazosin Tablets Due to Wrong Imprints
Unichem Pharmaceuticals (USA), Inc. has initiated a voluntary Class III recall of Doxazosin Tablets, USP, 4 mg, lot GDSH25006, due to incorrect tablet imprints. This nationwide distribution event, originating from Unichem Laboratories Limited in India, impacts supply chains for a critical human prescription drug, necessitating immediate action from procurement and regulatory teams.
FDA Class III Recall: Unichem's Doxazosin Tablets Imprinted with Wrong ID
Unichem Pharmaceuticals (USA), Inc., based in East Brunswick, NJ, has initiated a voluntary Class III recall for specific lots of its Doxazosin Tablets, USP, 4 mg. The recall, identified as D-0306-2026, was initiated on January 21, 2026, and classified by the FDA on February 11, 2026. The core issue stems from tablets being imprinted with the wrong identification, specifically affecting lot number GDSH25006, which carries an expiration date of August 2027. This particular lot, distributed under NDC 29300-353-10, involves a significant quantity of 60,000 tablets. For procurement directors and supply chain VPs, this means an immediate need to quarantine and return any affected inventory to prevent further distribution of mislabeled product. While a Class III recall indicates that the product is unlikely to cause adverse health consequences, the regulatory imperative to remove non-compliant drugs from the market remains absolute, impacting operational continuity and requiring swift logistical adjustments. Regulatory affairs heads must ensure their organizations are fully compliant with the recall instructions to mitigate any secondary compliance risks.
Global Manufacturing Footprint: Unichem's Doxazosin Mesylate Production in India
The recalled Doxazosin Tablets, USP, 4 mg, a human prescription drug containing Doxazosin Mesylate (ANDA212329), are manufactured by Unichem Laboratories Limited at their facility located in Pilerne Industrial Estate, Pilerne, Bardez, Goa, India (postal code 403511). Unichem Pharmaceuticals (USA), Inc. acts as the distributor from its East Brunswick, NJ, location. This global manufacturing and distribution model is common in the generic pharmaceutical industry, leveraging international production capabilities for the U.S. market. The product is available under several NDCs, including 29300-351, 29300-352, 29300-353, and 29300-354, with the specific recalled lot tied to 29300-353-10. For business development executives and procurement teams, this incident underscores the critical importance of rigorous due diligence on overseas manufacturing partners. It highlights that even seemingly minor quality control failures, such as incorrect imprinting, can lead to significant supply chain disruptions and regulatory actions, regardless of the product's origin. Ensuring robust quality agreements and audit programs for all international suppliers is paramount to safeguard product integrity and market supply.
Supply Chain Vulnerability: Nationwide Distribution of Recalled Doxazosin Lots
The distribution pattern for the affected Doxazosin Tablets, USP, 4 mg, lot GDSH25006, is described as 'Nationwide' across the United States. This broad reach amplifies the complexity and impact of the recall for all stakeholders in the pharmaceutical supply chain. Procurement directors must immediately assess their inventory across all distribution centers and pharmacies to identify and segregate the affected 60,000 tablets. The Class III classification, while indicating a low probability of adverse health consequences, does not diminish the operational burden. Supply chain VPs face the challenge of managing returns, potential stock-outs, and ensuring continuity of supply for Doxazosin Mesylate, a medication used for hypertension and benign prostatic hyperplasia. This event serves as a critical reminder that even voluntary, firm-initiated recalls for seemingly minor defects can create significant logistical challenges and necessitate rapid response to maintain patient access and regulatory compliance. Companies must have robust recall procedures in place to minimize market disruption and financial losses.
Broader Regulatory Environment: FDA's Heightened Scrutiny on Pharmaceutical Quality
This voluntary Class III recall by Unichem Pharmaceuticals (USA), Inc. occurs within a broader landscape of increasing regulatory scrutiny from the FDA on pharmaceutical quality and manufacturing compliance. Recent parallel events highlight this trend, including Class II recalls for Essential Wellness Pharma's Progesterone Injection due to sterility failures, Spectra Medical Devices' Lidocaine HCl Injection facing similar sterility assurance deficiencies, and Guardian Drug Co. Inc.'s nationwide recalls for metallic contamination in Calcium Carbonate Antacids. While Unichem's issue pertains to incorrect imprinting rather than sterility or contamination, these collective incidents underscore the FDA's consistent focus on ensuring product quality across all facets of drug manufacturing and labeling. For regulatory affairs heads and business development executives, this signals an imperative to invest continuously in robust Quality Management Systems (QMS) and to conduct thorough internal audits. The regulatory environment demands proactive compliance, as even seemingly minor deviations can trigger costly recalls, erode market trust, and potentially lead to more severe enforcement actions in the future, impacting market access and brand reputation.
Post-Recall Actions: Unichem's Remediation Path and Market Confidence
As a firm-initiated, voluntary recall with an 'Ongoing' status, Unichem Pharmaceuticals (USA), Inc. is now responsible for a comprehensive investigation into the root cause of the incorrect tablet imprints. This will involve identifying why lot GDSH25006 was mislabeled and implementing robust corrective and preventive actions (CAPA) to prevent recurrence. For procurement directors, monitoring Unichem's remediation progress is crucial. A transparent and effective resolution process will be key to restoring confidence in Unichem's quality systems and ensuring the long-term reliability of Doxazosin Mesylate supply. Failure to adequately address the underlying issues could lead to further regulatory scrutiny, including potential Warning Letters or even Import Alerts for the manufacturing facility in Goa, India, impacting future market access for their products. Business development executives should evaluate the potential for reputational damage and its impact on future contracts, while regulatory affairs teams must ensure all communications and documentation align with FDA expectations to demonstrate full compliance and commitment to quality.